The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

As per The Business Research Company’s Scleroderma Global Market Report 2023, The global scleroderma market is expected to grow from $2 billion in 2022 to $2.15 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The scleroderma market is expected to reach $2.78 billion in 2027 at a CAGR of 6.6%.

What was the major driver in the scleroderma market?

The greater prevalence of scleroderma is driving the scleroderma market going forward. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, in June 2022, according to Karger Publishers, a Switzerland-based publisher of peer-reviewed journals, 19,000 people had scleroderma in the UK and 2.5 million people worldwide. Furthermore, in July 2021, a research article published by Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, revealed that the global prevalence of scleroderma was 17.6 cases per 100,000 people and the incidence rate was 1.4 cases per 100,000 person-years. As a result, the greater prevalence of scleroderma is driving the scleroderma market.

View More On The Scleroderma Market Report 2023 – https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

What was the key trend in the scleroderma market?

Developing novel treatments is a key trend gaining popularity in the scleroderma market. Major companies in the scleroderma market are developing novel drugs to manage the symptoms and sustain their position in the market. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics manufacturer, received regulatory approval for its novel systemic sclerosis-related interstitial lung disease drug efzofitimod from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is a First-in-class immunomodulator to downregulate and control the immune response by modulating the neuropilin-2 (NRP2) receptor to reduce symptoms of scleroderma. Additionally, Efzofitimod also targets the same immune cells responsible for the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, leading to reduced pro-inflammatory markers in a clinical study with patients suffering from pulmonary sarcoidosis.

Which was the largest region in the scleroderma market?

North America was the largest region in the scleroderma market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleroderma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the scleroderma market prominent players?

Major players in the scleroderma market are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., and H.A.C. Pharma.

Key scleroderma market segments

The global scleroderma market is segmented –

1) By Treatment: Medication, Surgery, Other Treatments

2) By Indication: Systemic Scleroderma, Localized Scleroderma

3) By End User: Hospital, Pharmaceutical Stores, Other End Users

Request A Sample Of The Global Scleroderma Market Report 2023:

https://www.thebusinessresearchcompany.com/sample_request?id=12615&type=smp

The Scleroderma Global Market Report 2023  provides a comprehensive overview on the scleroderma market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –

Autoimmune Treatment Global Market Report 2023

Dermal Filler Global Market Report 2023

Dermatitis Global Market Report 2023

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model